BIO-TECH Systems, Inc. - Report #330: The U.S. Market for SPECT and PET Radiopharmaceuticals

Market Research in the Healthcare Field with Expertise in Medical Imaging and Radioisotopes

Bio-Tech Systems, Inc. - 4167 West Pinecrest Circle - Las Vegas, Nevada 89121 phone: (702) 456-7608 - fax: (702) 456-2189


	HOME

	ABOUT BIO-TECH SYSTEMS

	AUTHOR'S C.V.

	CLIENT LIST

	BREAKING MARKET NEWS

	REPORT #340 The Market for PET Radiopharmaceuticals & PET Imaging New! Released in Dec. 2011!

	REPORT #330 The U.S. Market for SPECT and PET Radiopharmaceuticals New! Released in Jun. 2011!
Report Contents
List of Exhibits

	REPORT #290 The U.S. Market for Brachytherapy Products New! Released in Mar. 2009!

	REPORT #260 The U.S. Market for Medical Imaging Contrast Media

	REPORT #230 The World Market for Therapeutic Radiopharmaceuticals

	ORDERS

	NEWS RELEASES

	CONTACT US

THE U.S. MARKET FOR SPECT AND PET RADIOPHARMACEUTICALS

BIO-TECH SYSTEMS INC. announces the publication of:

BIO-TECH Report #330, The U.S. Market for SPECT and PET Radiopharmaceuticals

The Radiopharmaceutical Report Includes:

Analysis of Current and Future Radiopharmaceutical Markets
Emerging Markets For New Molecular Imaging Platforms
Good Growth Prospects for New SPECT and PET Radiopharmaceuticals
Effect Of Technetium Supply Instabilities on The SPECT
Good Prospects for New PET Cardiology Products and Rubidium PET
Big Markets for New PET and SPECT Agents for Alzheimer's and Parkinson's
Promising New PET Oncology Products with Broad Applications
Technological Trends and Competitive Challenges
Market Assessment and Sales Forecasts to 2018

The report has a strong focus on new products and technology and emerging market opportunities. This includes nuclear cardiology with both PET and SPECT, targeted oncology and new broad-based molecular imaging platforms. It also analyzes the large emerging markets for imaging Alzheimer's and Parkinson's disease with PET and SPECT. This will broaden the base of molecular imaging. There was some decline in the number of SPECT myocardial perfusion procedures recently but this has stabilized. Most technetium users weathered the shortage without long-term damage. Supplies are now plentiful although prices have increased because the supply contracts are now negotiated on a short-term basis. The market has easily absorbed these increases because of the saving from the use of generic sestamibi and decline in price of myocardial perfusion agents.

PET perfusion agents for cardiology will offer capabilities for diagnosing complex cases and encourage more physicians to adopt PET for cardiology applications. Cardiology PET produces better images and offers higher reimbursement than traditional cardiology SPECT. Growth is also expected in cardiology SPECT from new products for imaging myocardial infarction and neuronal imbalances in patients at risk of congestive heart failure. .

New molecular imaging modalities are being developed based on apoptosis, angiogenesis and cellular proliferation. Other agents are in the pipeline for imaging slow growing tumors not easily visualized with either PET or SPECT. New oncology products are also being developed for diagnosing and monitoring cellular response to therapy. These molecular imaging platforms will also have therapeutic applications, increasing their versatility and usefulness. In the long run, this will encourage more investment from biopharmaceutical companies and venture groups that will enhance future market growth

SPECT and PET Radiopharmaceuticals: Market Analysis and Prospects
U.S. sales of SPECT and PET radiopharmaceuticals reached $1.2 billion in 2010 and are expected to rise to $6.0 billion by 2018. Total SPECT radiopharmaceutical sales were down 9.0% in 2010 primarily due to reductions in pricing of perfusion agents and increased use of generic sestamibi. SPECT procedure volume was also down due to the technetium shortage. This situation stabilized toward the end of 2010 with the two primary nuclear reactors back on line.

In comparison, PET procedures increased 8.9% to 2.1 million and revenue increased to $391.4 million, consistent with procedure growth. Although PET reimbursement has been under pressure, there has been relief in some areas recently. New clinical indications have been approved and reimbursement was favorable for cardiology procedures. Investment has been increasing in new PET agents and many of these products have entered late-stage development with market entry expected in the near future.

Continuing improvements in imaging technology for both SPECT and PET are allowing higher resolution and shorter imaging times. Radiopharmaceutical doses are also being pared down as a result of increased imaging efficiency. This makes nuclear medicine safer than many other imaging modalities that are threatened with excessive radiation and patient safety issues.

As new products are introduced, SPECT sales should increase from $758 million in 2010 to $1.68 billion by 2018, while PET sales should increase from $391.8 million to $4.31 billion by 2018. PET sales will increase more rapidly than SPECT due to more new products as well as increases in the volume of FDG procedures. Market growth will also result from higher prices of the new products. This influx of new products will help all segments of molecular imaging and create a good platform for continued growth for both SPECT and PET. One effect is that clinicians will have more options as alternatives to higher risk and more costly invasive procedures. This will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field.

Please follow one of the links below, or on the left, to find out more information about BIO-TECH Report #330. If you are interested in purchasing BIO-TECH Report #330, please follow this link to our Online Order Form.

To download a detailed Table of Contents (TOC) for BIO-TECH Report #330, please click on one of the two links below. The documents are a Microsoft Word 97-2000 file and an Adobe Acrobat 6 PDF file.

Download TOC in MS Word format (111KB)

Download TOC in Adobe PDF format (69KB)

Report Contents | Partial List of Exhibits

Report #330 Home Page

Download Report #330 Table of Contents:

BTSI330.doc -OR-

BTSI330.pdf

Send this page to a friend